Clinical Study of DEB-TACE and Sorafenib in the Treatment of Intermediate and Advanced Hepatocellular Carcinoma
Objective:To investigate the effects of transcatheter arterial chemoembolization with drug-eluting beads(DEB-TACE)combined with Sorafenib on serum tumor markers and liver function in patients with intermediate and advanced hepatocellular carcinoma(HCC).Method:A total of 120 patients with intermediate and advanced HCC treated in Guixi People's Hospital from June 2020 to June 2022 were selected,divided to the control group and the study group by random number table method,with 60 cases in each group.The control group was treated with conventional transcatheter arterial chemoembolization combined with Sorafenib,and the study group was treated with DEB-TACE combined with Sorafenib.The clinical efficacy of the two groups after 3 months of treatment were compared;the levels of serum tumor markers[vascular endothelial growth factor(VEGF),carcinoembryonic antigen(CEA),alpha-fetoprotein(AFP)]and liver function indicators[total bilirubin(TBIL),alanine aminotransferase(ALT),aspartate aminotransferase(AST)]before and after treatment were compared between the two groups;the progression-free survival(PFS),overall survival(OS)and occurrence of adverse reactions were compared between the two groups.Result:The objective remission rate of the study group(65.00%)was significantly higher than that of the control group(40.00%),the difference was statistically significant(P<0.05).Compared with the control group,the serum VEGF,CEA and AFP levels in the study group after treatment were lower,the differences were statistical significance(P<0.05).Compared with the control group,the serum AST,ALT and TBIL levels in the study group after treatment were lower,the differences were statistical significance(P<0.05).Compared with the control group,the PFS and OS of the study group were significantly prolonged,the differences were statistically significant(P<0.05).The incidences of adverse reactions between the two groups showed no significant differences(P>0.05).Conclusion:DEB-TACE combined with Sorafenib in the treatment of HCC can significantly improve the objective response rate of patients with intermediate and advanced HCC,prolong survival time,regulate the level of serum tumor markers,and reduce the incidence of liver function impairment.
Transcatheter arterial chemoembolization with drug-eluting beadsSorafenibHepatocellular carcinomaTumor markersLiver function
万方数据
维普
